3.5 Medication-Related Osteonecrosis of the Jaw (MRONJ) Risk & Management
Key Takeaways
- MRONJ diagnostic criteria require exposed bone or bone probed through a fistula persisting >8 weeks, current/prior exposure to antiresorptive or anti-angiogenic agents, and NO history of radiation therapy or metastatic disease in the jaws.
- Oncology patients receiving high-dose intravenous bisphosphonates or monthly subcutaneous Denosumab carry a significantly higher risk of MRONJ (1-15%) compared to osteoporosis patients (<0.1%).
- Stage 1 MRONJ consists of exposed bone or fistula without pain or infection and is managed conservatively with 0.12-0.2% Chlorhexidine mouthwash.
- Stage 2 MRONJ involves exposed bone with pain and systemic infection, requiring systemic oral antibiotics alongside antimicrobial rinses and superficial debridement.
- Drug holidays for bisphosphonates are not routinely supported by clinical evidence due to long-term skeletal accumulation; Denosumab drug holidays carry severe risks of rebound vertebral fractures.
3.5 Medication-Related Osteonecrosis of the Jaw (MRONJ) Risk & Management
Medication-Related Osteonecrosis of the Jaw (MRONJ) is a severe, potentially debilitating drug-induced osteonecrosis affecting the maxilla and mandible. Dentists playing a critical role in pre-therapy dental clearance, risk mitigation, early diagnosis, and conservative surgical management according to guidelines established by the Australian Dental Association (ADA) and American Association of Oral and Maxillofacial Surgeons (AAOMS).
Diagnostic Criteria for MRONJ
To establish a clinical diagnosis of MRONJ, all three of the following criteria must be satisfied:
- Exposed Bone or Fistula: Current exposed bone in the maxillofacial region OR intraoral/extraoral bone that can be probed through a fistula, persisting for more than 8 weeks.
- Pharmacological Exposure: Current or prior treatment with antiresorptive agents (bisphosphonates, denosumab) or anti-angiogenic therapies.
- Absence of Radiation / Metastasis: No history of radiation therapy to the jawbones and no primary metastatic disease involving the jaws.
+---------------------------------------------------------------------------------------------------+
| MRONJ DIAGNOSTIC TRIAD REQUIREMENT |
| |
| Exposed Bone / Probed Fistula > 8 Weeks + Antiresorptive / Anti-Angiogenic Drug History |
| + |
| NO Prior Radiation Therapy to Jaws / NO Local Metastasis |
+---------------------------------------------------------------------------------------------------+
Pharmacological Classes Implicated in MRONJ
1. Antiresorptive Agents
- Bisphosphonates: Synthetic analogues of inorganic pyrophosphate that bind selectively to hydroxyapatite crystals in bone matrix. During osteoclastic bone resorption, bisphosphonates are internalized by osteoclasts, inhibiting farnesyl pyrophosphate (FPP) synthase, triggering osteoclast apoptosis and suppressing bone remodeling.
- Oral Formulations (Osteoporosis): Alendronate (Fosamax), Risedronate (Actonel), Ibandronate.
- Intravenous Formulations (Oncology / Bone Metastases): Zoledronic Acid (Zometa 4 mg IV monthly for oncology; Aclasta 5 mg IV annually for osteoporosis), Pamidronate.
- RANKL Inhibitors: Denosumab is a human monoclonal antibody that binds to receptor activator of nuclear factor kappa-B ligand (RANKL), preventing RANKL from activating RANK on osteoclasts.
- Prolia: 60 mg subcutaneous injection every 6 months (Osteoporosis indication; lower risk profile).
- Xgeva: 120 mg subcutaneous injection monthly (Bone metastases / Multiple myeloma; high risk profile).
2. Anti-Angiogenic Agents
Interfere with vascular endothelial growth factor (VEGF) signaling pathways, impairing new vessel formation and bone vascularity (e.g., Bevacizumab, Sunitinib, Sorafenib).
Patient Risk Stratification
The risk of developing MRONJ varies dramatically based on therapeutic indication, drug potency, cumulative dose, and route of administration.
| Risk Category | Clinical Indication & Drug Exposure | Estimated Incidence | Primary Risk Factors |
|---|---|---|---|
| Low Risk | Oral Bisphosphonates for Osteoporosis ($<4$ years duration); Subcutaneous Denosumab (Prolia 60 mg 6-monthly $<4$ years) | 0.01% – 0.1% (1 in 1,000 to 1 in 10,000) | Duration $<4$ yrs, no systemic corticosteroids or co-morbidities |
| High Risk | IV Bisphosphonates (Zometa) or High-Dose Denosumab (Xgeva) for Oncology; Oral Antiresorptives $>4$ years; Concurrent systemic Corticosteroid use | 1% – 15% (1 in 100 to 1 in 7) | Dentoalveolar surgery (extractions ~60-70% of triggers), poor oral hygiene, ill-fitting dentures, anemia, diabetes |
KEY TAKEAWAY ON RISK:
Oncology regimens (monthly IV Zoledronic acid or monthly Denosumab) carry a risk up to
100-fold HIGHER than standard oral osteoporosis therapy.
Clinical Staging & Management Protocols (AAOMS / ADA)
| Stage | Clinical & Radiographic Presentation | Recommended Management Protocol |
|---|---|---|
| At Risk | No exposed bone, asymptomatic; patient taking antiresorptives | Patient education, oral hygiene optimization, routine dental care |
| Stage 0 | No clinical bone exposure, but non-specific symptoms (unexplained jaw pain, loose teeth, sinus pain, altered bone density) | Conservative symptom management, radiographic monitoring, pain control |
| Stage 1 | Exposed necrotic bone or fistula probing to bone; Asymptomatic with No evidence of infection or swelling | Topical antimicrobial mouthwashes (0.12–0.2% Chlorhexidine bid); regular clinical follow-up; avoid operative intervention |
| Stage 2 | Exposed bone or fistula probing to bone WITH Pain, Erythema, and Local Infection (with/without purulent drainage) | Oral Systemic Antibiotics (e.g., Amoxicillin 500 mg tid + Metronidazole 400 mg tid) + 0.2% Chlorhexidine + superficial soft tissue debridement |
| Stage 3 | Exposed bone extending beyond alveolar bone (inferior border, ramus, maxillary sinus), Pathological Fracture, extraoral fistula, or oroantral communication | Surgical Debridement / Resection, IV antibiotics, pain management, microvascular reconstruction |
Pre-Therapy Dental Clearance & Prevention Strategies
Patients About to Initiate High-Dose Antiresorptive / Oncology Therapy
- Comprehensive Examination: Full clinical and radiographic assessment (Bitewing and OPG/CBCT).
- Eliminate Foci of Infection: Extract non-restorable teeth, teeth with poor periodontal prognosis (probing depths $>6\text{ mm}$, mobility class II/III), and hopeless impacted molars.
- Allow Mucosal Healing: Delay commencement of oncology antiresorptive therapy for 14 to 21 days post-extraction to allow complete epithelialisation and primary mucosal closure over socket sites.
- Prophylaxis & Hygiene: Perform full-mouth scaling, restorative care, and patient oral hygiene instruction.
Patients Currently Receiving Antiresorptive Therapy Requiring Dental Procedures
- Prefer Non-Invasive Procedures: Endodontic therapy (with coronal tooth sectioning if non-restorable) is strongly preferred over tooth extraction to avoid bone exposure.
- Preventive Surgical Protocol (If Extraction Unavoidable):
- Perform atraumatic exodontia with minimal periosteal elevation.
- Smooth sharp alveolar bone margins (alveoloplasty) to eliminate bony spicules.
- Achieve primary mucosal closure without tension using resorbable sutures.
- Administer perioperative antibiotic prophylaxis (e.g., Amoxicillin 500 mg 8-hourly starting 24h prior and continuing 5-7 days post-operatively).
- Prescribe 0.2% Chlorhexidine mouthwash twice daily for 2 weeks.
The "Drug Holiday" Controversy
- Bisphosphonates: Bisphosphonates bind irreversibly to bone mineral and persist in the skeleton for up to 10 years. Discontinuing oral bisphosphonates for short periods ("drug holiday") prior to dental surgery provides no proven reduction in MRONJ risk.
- Denosumab: Denosumab does not incorporate into bone matrix; its antiresorptive effects wane rapidly 6 months after injection. However, initiating a drug holiday from Denosumab triggers a rebound surge in osteoclast activity, leading to rapid bone loss and severe risk of multiple rebound vertebral fractures. Denosumab therapy must NEVER be interrupted without explicit consultation with the patient's endocrinologist/oncologist.
Which of the following clinical presentations satisfies the formal diagnostic criteria for Medication-Related Osteonecrosis of the Jaw (MRONJ)?
A 65-year-old female patient diagnosed with postmenopausal osteoporosis has been receiving subcutaneous Denosumab (Prolia 60 mg) injections every 6 months for the past 2 years. She requires extraction of a unrestorable fractured premolar. What is the most appropriate management regarding her Denosumab regimen prior to extraction?
A 72-year-old male receiving monthly intravenous Zoledronic acid for prostate cancer bone metastases presents with an area of exposed, necrotic bone in the left posterior mandible measuring 1.5 cm. The area is painful, inflamed, and discharging purulent exudate. According to AAOMS clinical staging, what stage is this lesion and how should it be managed?
A 60-year-old patient with multiple myeloma is scheduled to commence high-dose intravenous bisphosphonate therapy (Zoledronic acid) in 4 weeks. What is the primary objective of the pre-therapy dental clearance evaluation?